Coverage
-
March 24, 2015
The lead plaintiff in an investor class action against now-bankrupt experimental drug company PolyMedix Inc. asked a Pennsylvania federal judge on Monday to approve a $1.15 million settlement with nearly $400,000 in attorneys' fees.
1 other articles on this case.
View all »